Is PDRN a peptide? Salmon DNA vs GHK-Cu, explained

The short answer: PDRN is not a peptide

PDRN stands for polydeoxyribonucleotide, a chain of DNA units. A peptide is a chain of amino acids. Both are molecular chains, but they are built from different chemical alphabets, and your skin cells understand both. The purification process for PDRN deliberately strips out residual peptides to avoid allergic reactions.

PDRN stands for polydeoxyribonucleotide. That is a long word, so let us break it apart. "Poly" means many, and "deoxyribonucleotide" means the chemical unit that makes up DNA. So PDRN is literally many DNA units linked together in a chain. A peptide is a different kind of chain: it is made of amino acids, the building blocks of proteins. Same idea (a chain of small pieces), different pieces.

Think of it like language. Both English and Spanish are languages, but they use different alphabets and different grammar. Peptides and PDRN are both molecular chains, but they speak different chemical alphabets. Your skin cells happen to understand both.

The confusion makes sense. PDRN and its longer-chain cousin PN are sold under names like Rejuran and Plinest, and they are marketed alongside peptides on skincare websites. But the molecules are chemically distinct. The purification process for PDRN actually removes any residual peptides on purpose, because leftover protein fragments could trigger an allergic reaction in the skin [1].

So what is PDRN actually made of?

PDRN is fragmented DNA extracted from the sperm cells of salmon trout or chum salmon. High-temperature purification turns it into an active substance more than 95 percent pure, with proteins and peptides inactivated. What remains is DNA fragments typically spanning 50 to 1500 kilodaltons, far larger than a copper peptide.

PDRN is fragmented DNA that comes mostly from the sperm cells of salmon trout or chum salmon. Yes, the "salmon DNA" headlines are accurate. The manufacturer extracts the raw fish DNA and purifies it at high temperature into an active substance more than 95 percent pure, with the proteins and peptides inactivated [1]. What is left behind is a mixture of DNA fragments typically spanning 50 to 1500 kilodaltons in size [2].

A kilodalton is just a unit of weight for very small things (1 dalton is roughly the weight of one hydrogen atom, and 1 kilodalton is 1000 of those). For comparison, GHK-Cu, a well-studied copper peptide, weighs about 0.4 kilodaltons. That is a big size difference, and it matters for how each molecule gets into your skin (more on that below).

You may also see the term polynucleotide biorevitalization or just PN. The two terms are closely related, and the 2025 review that mapped this field proposes drawing the line at 1500 kilodaltons: shorter chains are properly called PDRN, longer ones PN [2]. If you see Rejuran or Plinest on a clinic menu, they are brands, not molecules. Rejuran is described in its own trial as made from purified polynucleotides [6], which puts it on the PN side of that line, much as Ozempic is a brand built around semaglutide.

What does PDRN actually do in your skin?

PDRN binds the adenosine A2A receptor on fibroblasts, the cells that manufacture collagen and elastin. That triggers three things: more collagen output, calmer local inflammation, and new small blood vessels. A second route recycles the DNA fragments through the salvage pathway, handing the cell ready-made parts for DNA synthesis and repair.

Your skin has cells called fibroblasts. These are the workers that manufacture collagen and elastin, the two proteins that give young skin its bounce and firmness. As you age, fibroblasts slow down. Wrinkles, thin skin, and slow wound healing all trace back to less-productive fibroblasts.

PDRN wakes those workers up. Specifically, it binds to a receptor on the fibroblast surface called the adenosine A2A receptor. You can think of a receptor as a docking slot on the outside of the cell: when the right molecule clicks into the slot, the cell changes what it is doing. When PDRN clicks into the A2A slot, three things happen. The fibroblast starts making more collagen, it calms inflammation around itself, and it helps grow new tiny blood vessels, which means better nutrient delivery to the skin [3].

There is also a second mechanism that is actually kind of elegant. The DNA fragments in PDRN can be recycled by the cell through something called the salvage pathway, an energy-saving route that reuses ready-made nucleotides and nucleosides instead of building DNA components from scratch [4]. PDRN essentially hands the fibroblast a stack of pre-made parts that it can put toward DNA synthesis, repair and growth [4].

How GHK-Cu compares: a real peptide with different strengths

GHK-Cu is a tripeptide, three amino acids bound to a copper ion, first identified in human blood plasma in 1973. Besides raising collagen synthesis, it changes the activity of thousands of genes. At roughly 0.4 kilodaltons it is small enough to penetrate skin from a topical serum.

GHK-Cu is where peptides enter the conversation. The name is short for glycyl-L-histidyl-L-lysine bound to a copper ion. That literally just describes its recipe: three amino acids (glycine, histidine, lysine) linked in a tiny chain, with one atom of copper attached. The full molecule is only three amino acids long, which is why it is called a tripeptide.

GHK-Cu was first identified in human blood plasma in 1973, and it has been studied in dermatology for decades. Besides increasing collagen, elastin, and glycosaminoglycan synthesis, it changes which genes are turned on or off: in one gene-expression analysis, 31.2 percent of human genes shifted their activity by 50 percent or more in response to GHK [5].

Because GHK-Cu is so small (remember, 0.4 kilodaltons versus PDRN's 50 to 1500), it can actually penetrate skin from a topical serum. That is a huge practical difference. You can buy a GHK-Cu serum online for under $30 and apply it at home. PDRN, because the molecule is so much larger, has to be injected directly into the dermis (the layer of skin below the surface where fibroblasts live) to have a real effect. That means a clinic visit, a trained injector, and several hundred dollars per session.

Head-to-head: what actually matters for your decision

Both ingredients are studied for raising collagen production and calming inflammation. They differ on delivery, evidence, regulation, and cost. The best-known phase III trial of a polynucleotide injectable (Rejuran) against hyaluronic acid filler found no significant difference in patients and was retracted in 2016; GHK-Cu owns decades of dermatology literature and gene-expression data, at a fraction of the price.

Both ingredients are studied for increasing collagen production and calming inflammation in skin. Where they differ is how you get them in, how strong the evidence is, and how much they cost.

For evidence, neither ingredient has a clean clinical win. The best-known trial of a polynucleotide injectable, a phase III randomized double-blind study published in 2014, treated crow's feet (the fine lines near the outer eye) in 72 patients with a polynucleotide filler (Rejuran) on one side of the face and a hyaluronic acid filler on the other. In those patients, the primary and secondary efficacy outcomes showed no statistically significant difference between the two sides; the gains in elasticity, collagen and wrinkle depth the paper reported came from its mouse study [6]. The journal retracted the paper in 2016 [8]. GHK-Cu does not have a head-to-head trial either, but it has a much larger body of general dermatology literature going back to the 1980s, plus a genome-wide gene-expression profile of a kind PDRN does not have.

The wider human evidence is no cleaner. A 2024 review of polynucleotides across aesthetic medicine found the human evidence genuinely mixed: some studies showed meaningful gains in skin elasticity and hydration, while others reported limited or no benefit, and the authors concluded that more research is needed to establish where these treatments actually help [7]. A handful of mixed studies is not the same as a settled ingredient.

For regulation, there is an asymmetry worth knowing. Rejuran injectables are not FDA approved in the United States as of April 2026. They are legal in South Korea, parts of Europe, and much of Southeast Asia, and some US clinics offer them anyway. That is not off-label use, which means prescribing an FDA-approved product for another purpose; Rejuran has no FDA approval at all. Topical GHK-Cu is not a regulated drug in the US: in serums it is classified as a cosmetic ingredient, which is why you can buy it on Amazon. Neither status is a red flag by itself, but if you want an injectable with full FDA oversight, Rejuran is not that today.

For cost, topical GHK-Cu serum runs $20 to $80 per bottle and lasts roughly two months. A Rejuran treatment course at a US clinic that offers it typically runs $500 to $1000 per session with 3 to 4 sessions suggested before results are assessed. Those are market prices rather than a published figure, but the gap is the point: at those prices a year of serum (about six bottles) comes to roughly $120 to $480, while one injection course comes to $1,500 to $4,000.

So which one should you consider?

It depends on three things: your actual goal, how reactive your skin is, and whether your budget and needle tolerance can absorb clinic visits. The helper below asks those three questions and lays out what the evidence says for your situation, plus what to ask a dermatologist. It describes evidence; it does not prescribe.

Honest answer: it depends on your goal, your budget, and how comfortable you are with needles. Rather than guessing, the tool below walks you through the three questions that actually determine the answer. Pick your main goal, how your skin behaves, and your budget range, and it will show which of the two can fit that situation, what the evidence behind each one looks like, and the questions worth taking to a dermatologist. It is a way to read the evidence, not a treatment plan.

The bigger picture: your skin cares about signaling, not labels

Both molecules work because they send signals to skin cells, and your skin does not care whether a signal arrived as a peptide, a DNA fragment, or a retinoid. The useful question is not "is this a peptide?" but "does this signal the thing I want, and can it reach the right cells?"

Here is the punchline that matters more than the peptide-versus-DNA technicality. Both PDRN and GHK-Cu work because they send signals to your skin cells. Your skin does not know (or care) whether the signal came from a peptide, a DNA fragment, a growth factor, or a retinoid. What matters is whether the signal reaches the right cells and tells them to do something useful.

That framing is why the question "is this a peptide?" is less useful than "does this signal the thing I want?" Peptides get most of the marketing because the word sounds scientific and clean. PDRN gets the hype in 2026 because it sounds exotic and novel. In terms of what actually makes skin better, both categories are part of the same bigger toolkit of cellular signaling molecules. Ingredients that have been around a long time (retinoids, vitamin C, niacinamide) work through completely different signals and still get results. PDRN and GHK-Cu are not magic, they are just well-characterized ways of nudging fibroblasts in the right direction.

Skin quality is also affected by factors that have nothing to do with which ingredient you apply. Chronically elevated cortisol accelerates collagen breakdown and slows wound repair, the same fibroblast pathways both PDRN and GHK-Cu try to upregulate. If stress-related skin changes like puffiness, adult acne, or slow healing are part of your picture, the cortisol face guide covers the mechanism and what actually helps. Separately, advanced glycation end-products from a high-sugar diet create cross-links in collagen that neither ingredient can reverse; the sugar face guide explains that pathway and how to reduce it upstream. For context on where injectable treatments like Botox sit relative to PDRN on the same clinical evidence spectrum, the guide to how Botox works covers the neuromuscular mechanism and evidence tier.

If you want the full mechanism and clinical evidence for GHK-Cu, our GHK-Cu mastery course covers the gene-expression data, the specific wound-healing pathways, and how topical and injected delivery compare. For the peptide side of the equation, that is the deepest reference we have. If you are starting from scratch, the free foundations course covers how peptides work before you spend anything.